Drug profile · INN
pneumococcal polysaccharide conjugate vaccine (21-valent)
CAPVAXIVE
pneumococcal polysaccharide conjugate vaccine (21-valent) (CAPVAXIVE) is an FDA-listed pharmaceutical active ingredient.
EMA: approved Antiinfectives for systemic use (J07) J07AL02
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — pneumococcal polysaccharide conjugate vaccine (21-valent)
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
pneumococcal polysaccharide conjugate vaccine (21-valent) (CAPVAXIVE) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN pneumococcal polysaccharide conjugate vaccine (21-valent)
Brand CAPVAXIVE
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07AL02
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is pneumococcal polysaccharide conjugate vaccine (21-valent)?
pneumococcal polysaccharide conjugate vaccine (21-valent) (CAPVAXIVE) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for pneumococcal polysaccharide conjugate vaccine (21-valent)?
CAPVAXIVE is a marketed brand name for pneumococcal polysaccharide conjugate vaccine (21-valent). Check FDA Drugs@FDA for the current US label holder and prescribing information.